Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Irvine UCLA
Dates
study started
completion around

Description

Summary

Official Title

A Phase 1/1b Study of ASP2138 as Monotherapy and in Combination With Pembrolizumab and mFOLFOX6 or Ramucirumab and Paclitaxel in Participants With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination With mFOLFIRINOX in Participants With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression

Keywords

Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma, Claudin (CLDN) 18.2, ASP2138, Pharmacokinetics, Safety, Tolerability, Adenocarcinoma, Leucovorin, Paclitaxel, Pembrolizumab, Oxaliplatin, Fluorouracil, Irinotecan, Ramucirumab

Eligibility

Locations

  • University of California Irvine Medical Center accepting new patients
    Orange California 92868 United States
  • UCLA Dept of Medicine - Hematology/Oncology, Santa Monica withdrawn
    Santa Monica California 90404 United States
  • Virginia Mason Medical Center accepting new patients
    Seattle Washington 98101 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Astellas Pharma Global Development, Inc.
ID
NCT05365581
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 378 study participants
Last Updated